TD Cowen initiated a $24 price target for Roivant Sciences (ROIV) following the release of its announcement that its Brepo 30mg dose succeeded in Ph3 VALOR DM with robust and consistent statistical signifiant efficacy on all key endpoints.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences price target raised to $20 from $18 at Jefferies
- Roivant Sciences price target raised to $21 from $15 at Guggenheim
- Roivant Sciences price target raised to $20 from $16 at JPMorgan
- Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright
- Yaron Werber’s Buy Rating Highlights Brepocitinib’s Potential as a Leading Treatment for Dermatomyositis